Penumbra Inc (NYSE:PEN) insider Daniel Donen Davis sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $88.80, for a total value of $2,664,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Penumbra Inc (NYSE PEN) traded up $0.65 during mid-day trading on Thursday, hitting $90.10. The company’s stock had a trading volume of 298,902 shares, compared to its average volume of 403,355. Penumbra Inc has a 1 year low of $67.95 and a 1 year high of $116.35. The stock has a market cap of $2,959.45, a P/E ratio of -409.55, a price-to-earnings-growth ratio of 93.43 and a beta of 0.16.

Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.07. Penumbra had a negative return on equity of 1.95% and a negative net margin of 2.19%. The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $79.17 million. During the same quarter in the prior year, the business earned ($0.04) EPS. The business’s revenue for the quarter was up 24.9% on a year-over-year basis. research analysts predict that Penumbra Inc will post -0.15 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. grew its holdings in shares of Penumbra by 5.2% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 138,468 shares of the company’s stock worth $13,030,000 after acquiring an additional 6,884 shares during the period. Simplex Trading LLC boosted its position in shares of Penumbra by 116.2% in the 4th quarter. Simplex Trading LLC now owns 1,911 shares of the company’s stock worth $179,000 after purchasing an additional 1,027 shares in the last quarter. Pura Vida Investments LLC boosted its position in shares of Penumbra by 19.2% in the 3rd quarter. Pura Vida Investments LLC now owns 59,579 shares of the company’s stock worth $5,380,000 after purchasing an additional 9,579 shares in the last quarter. Neuberger Berman Group LLC boosted its position in shares of Penumbra by 0.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 250,500 shares of the company’s stock worth $22,620,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Penumbra in the 3rd quarter worth approximately $374,000. Hedge funds and other institutional investors own 71.71% of the company’s stock.

A number of research analysts recently issued reports on the company. Canaccord Genuity boosted their price target on Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets upped their target price on Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. JPMorgan Chase & Co. downgraded Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, Zacks Investment Research upgraded Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $111.50.

WARNING: This piece of content was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/01/18/daniel-donen-davis-sells-30000-shares-of-penumbra-inc-pen-stock.html.

About Penumbra

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.